Losartan attenuates human monocyte-derived dendritic cells immune maturation via downregulation of lectin-like oxidized low density lipoprotein receptor-1
Journal of Cardiovascular Pharmacology,  Clinical Article

Huang D et al. – Losartan could attenuate the oxLDL– and Ang II–induced immune maturation of human monocyte–derived DCs partly through downregulation of the LOX–1 expression.

  • The angiotensin II receptor 1 blockers (ARBs) have generally been shown to have anti–atherogenic effects and dendritic cells (DCs) are the most efficient antigen presenting cells that play an active role in the development of atherosclerosis through inflammatory–immune responses.
  • Here, authors tested the hypothesis that the anti–atherogenic effect of losartan, the first ARB, might partly be mediated by attenuating DCs maturation.
  • In this study authors showed that oxidized low density lipoprotein (oxLDL) and angiotensin II (Ang II) could induce the maturation of human monocyte–derived DCs, stimulate CD83, HLA–DR expressions and IL–12, IFN–[gamma] secretions and increase the capacity of DCs to stimulate T–cell proliferation, which were suppressed by losartan.
  • OxLDL could promote the autocrine secretion of Ang II by DCs and upregulate the expressions of three scavenger receptors SR–A, CD36 and LOX–1.
  • Losartan reduced oxLDL–induced LOX–1 expression, but not SR–A and CD36 expressions.
  • Ang II could only upregulate the LOX–1 expression, which was reduced by losartan. OxLDL– and Ang II–induced upregulation of CD83 and secretion of IL–12 were all attenuated by LOX–1 neutralizing antibody.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Endocrinology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Endocrinology Articles

1 Effects of 12 weeks high-dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – A double-blind, randomized, placebo-controlled trial Metabolism, July 9, 2014    Clinical Article

2 Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis Diabetes Care, October 24, 2014    Clinical Article

3 Seasonal variation in month of diagnosis in children with type 1 diabetes registered in 23 European centers during 1989-2008: little short-term influence of sunshine hours or average temperature Pediatric Diabetes, October 16, 2014    Clinical Article

4 Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator–controlled, adaptive proof-of-concept phase 2 study Diabetes Care, September 19, 2014    Clinical Article

5 Hemoglobin A1c less than 6.5% on admission increases risk for in-hospital and 1-year mortality in patients with diabetes and chest pain Cardiovascular Endocrinology, September 2, 2014    Clinical Article

6 Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study) The American Journal of Cardiology, October 3, 2014    Clinical Article

7 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 22, 2014    Clinical Article

8 The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008–2012 European Heart Journal: Acute Cardiovascular Care, October 1, 2014    Clinical Article

9 Latent autoimmune diabetes in adults with low-titer GAD antibodies: Similar disease progression with type 2 diabetes: A nationwide, multicenter prospective study (LADA China Study 3) Diabetes Care, October 24, 2014    Clinical Article

10 Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus The Journal of Clinical Pharmacology, October 20, 2014    Clinical Article

11 Effects of 12 weeks treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study European Journal of Endocrinology, October 13, 2014    Clinical Article

12 Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin Acta Diabetologica, October 15, 2014    Clinical Article

13 Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: The LIBRA Trial Diabetes Care, September 26, 2014    Clinical Article

14 Initial combination of linagliptin and metformin compared with linagliptin monotherapy in newly diagnosed type 2 diabetes patients with marked hyperglycaemia: a randomised, double-blind, active-controlled, parallel group, multinational clinical trial Diabetes, Obesity and Metabolism, October 10, 2014    Clinical Article

15 New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, September 12, 2014    Clinical Article

16 The pharmacokinetics of metformin and concentrations of HbA1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus British Journal of Clinical Pharmacology, October 9, 2014    Clinical Article

17 An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes Diabetes Care, September 12, 2014    Clinical Article

18 New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care, October 23, 2014    Clinical Article

19 The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus Canadian Journal of Diabetes, October 28, 2014    Review Article

20 Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus The Journal of Clinical Hypertension, October 24, 2014    Clinical Article

Indexed Journals in Endocrinology: Endocrinology, Journal of Endocrinology, Clinical Endocrinology, Diabetesmore